Sign In
Buy TENX
$12.25
+0.250 (+2.08%)
At Close: Jun 22, 2026
Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)
11:47am, Friday, 15'th Nov 2024
Tenax Therapeutics, Inc. (NASDAQ:TENX ) Guggenheim Healthcare Innovation Conference November 13, 2024 1:00 PM ET Company Participants Chris Giordano - President and CEO Stuart Rich - Chief Medical Off
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
07:00am, Wednesday, 13'th Nov 2024
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
04:05pm, Thursday, 31'st Oct 2024
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing
Why Is Tenax Therapeutics (TENX) Stock Up 29% Today?
11:05am, Tuesday, 06'th Aug 2024
Tenax Therapeutics (NASDAQ: TENX ) stock is soaring higher on Tuesday after the company announced the completion of an oversubscribed private placement for its shares. This oversubscribed private plac
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
07:13am, Tuesday, 06'th Aug 2024
CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focuse
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
08:00am, Tuesday, 14'th May 2024
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellec
CHAPEL HILL, N.C., April 30, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializin
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
08:30am, Thursday, 28'th Mar 2024
CHAPEL HILL, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializin
Tenax Therapeutics to Present at the 36th Annual Roth Conference
08:30am, Tuesday, 12'th Mar 2024
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializin
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
09:00am, Thursday, 29'th Feb 2024
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failu
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
08:30am, Tuesday, 20'th Feb 2024
CHAPEL HILL, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
08:53am, Thursday, 08'th Feb 2024
Tenax Therapeutics (NASDAQ: TENX ) stock is falling hard on Thursday after the pharmaceutical company announced details for a public offering of its shares. That public offering has Tenax Therapeutic
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
08:16am, Thursday, 08'th Feb 2024
CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that a
Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will recruit patients primarily from leading research
